Direkt zum Inhalt
Merck
  • A short dasatinib and quercetin treatment is sufficient to reinstate potent adult neuroregenesis in the aged killifish.

A short dasatinib and quercetin treatment is sufficient to reinstate potent adult neuroregenesis in the aged killifish.

NPJ Regenerative medicine (2023-06-17)
Jolien Van Houcke, Valerie Mariën, Caroline Zandecki, Rajagopal Ayana, Elise Pepermans, Kurt Boonen, Eve Seuntjens, Geert Baggerman, Lutgarde Arckens
ZUSAMMENFASSUNG

The young African turquoise killifish has a high regenerative capacity, but loses it with advancing age, adopting several aspects of the limited form of mammalian regeneration. We deployed a proteomic strategy to identify pathways that underpin the loss of regenerative power caused by aging. Cellular senescence stood out as a potential brake on successful neurorepair. We applied the senolytic cocktail Dasatinib and Quercetin (D + Q) to test clearance of chronic senescent cells from the aged killifish central nervous system (CNS) as well as rebooting the neurogenic output. Our results show that the entire aged killifish telencephalon holds a very high senescent cell burden, including the parenchyma and the neurogenic niches, which could be diminished by a short-term, late-onset D + Q treatment. Reactive proliferation of non-glial progenitors increased substantially and lead to restorative neurogenesis after traumatic brain injury. Our results provide a cellular mechanism for age-related regeneration resilience and a proof-of-concept of a potential therapy to revive the neurogenic potential in an already aged or diseased CNS.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Lectin from Wisteria floribunda, buffered aqueous solution, biotin conjugate
Sigma-Aldrich
Anti-sox2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution